The COVID-19 pandemic and the use of MS disease-modifying therapies

Mult Scler Relat Disord. 2020 Apr:39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.

¹ Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK. Electronic address: g.giovannoni@qmul.ac.uk.
² Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK.
³ School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
⁴ NMO Clinic and Research Laboratory, Division of Neuroimmunology & Neuroinfectious Disease, Massachusetts General Hospital, Boston, USA.
⁵ Department of Neurology, UC San Francisco, San Francisco, California, USA.
⁶ Blizard Institute, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, UK; The Albion Centre, Prince of Wales Hospital, Sydney, New South Wales, Australia.

No abstract available

MeSH terms